Ella J. Ariza-Heredia, MD

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Infectious Diseases

Ella J. Ariza-heredia, Md is currently serving as an Infectious Diseases Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Ella J. Ariza-Heredia, MD

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Phase 1/2 Study of Donor-Derived Anti-Cd33 Car T-Cell Therapy (Vcar33) for Relapsed/Refractory Aml After Allogeneic Hct. Blood (2026)

experimental medicineimmunotherapyhematologyleukemiastem cell transplantationphase 1/2radiation oncologyallogeneic hctbone marrow transplantationimmune responsescell transplantationcellular therapycell therapyrelapsed/refractory amlimmunologyclinical transplantation

Clinical Outcomes From the Pooled Safety Analysis of Cd19 Nex-T™ (Bms-986353), a Chimeric Antigen Receptor (Car) T Cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results From Phase 1 Breakfree Studies. Transplantation and Cellular Therapy (2026)

experimental medicineimmunotherapyrheumatologyrheumatismclinical outcomesimmune responsesclinical immunologyimmunomodulationmedicineclinical rheumatologycellular therapycell therapypooled safety analysisautoimmune diseasesphase 1immunologyautoimmunity

Idsa 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal Rsv Infections in Immunocompromised Patients. Clinical Infectious Diseases (2026)

medical virologyidsa 2025infection controlseasonal rsv infectionsvaccine developmentimmunocompromised patientsmedicinevaccine safetyinfectious diseasesvaccinationcommunicable diseasesvaccine efficacyinfectious diseases (medical specialty)vaccines

Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis. Transplantation and Cellular Therapy (2026)

leukemiahematologyhematological malignanciessystematic literature review/meta-analysisradiation oncologybone marrow transplantationoncologymedicinesurvival analysiscell transplantationinternational bloodcancer careclinical transplantationlymphoid neoplasiacomplete response

Administration of Off-The-Shelf, Expanded, Most Closely Hla Matched, Third Party Viral Specific T Cells for the Therapy of Adenovirus Related Disease in Adult Immunocompromised Patients.. Blood (2025)

medical virologyimmunotherapyantiviral responsesimmunity (medicine)adenovirus related diseaseadult immunocompromised patientsmedicinecell transplantationcellular therapyinfectious diseasescell therapyantiviral therapyimmunologyvirology

An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant. Clinical Infectious Diseases (2025)

medical virologyhematologystem cell transplantationimmunity (medicine)bone marrow transplantationphase 3medicinecell transplantationcell therapyinfectious diseasesimmunologyclinical transplantationplacebo-controlled trialletermovir prophylaxistransplantation medicine

Burden of Seasonal Human Coronavirus Infections in Hematopoietic Cell Transplant Recipients. Transplant Infectious Disease (2025)

medical virologycovid-19virus researchmedicinesars-cov-2covid-19 pandemicinfectious diseasestransplant infectious diseasesepidemiologycommunicable diseasesinfectious diseases (medical specialty)virus epidemiology

Ct-1192: Characterization of Infectious Complications Following Car T-Cell Therapy and the Need for Antibiotic Treatment During the Expected Period of Cytokine Release Syndrome. Clinical Lymphoma Myeloma & Leukemia (2025)

hospital infectionsimmunotherapyimmunosuppressioninfection controlexpected periodcellular immune responsesimmune responsesclinical immunologycytokine release syndromemedicinecellular therapyinfectious diseasescar t-cell therapyimmunology

How We Diagnose and Manage Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infection After Haematopoietic Cell Transplantation. Clinical Microbiology and Infection (2025)

medical virologyhematologystem cell transplantationmucocutaneous infectionclinical transplantationbone marrow transplantationgraft rejectionresistant herpesmedicinecell transplantationcell therapyinfectious diseasesvirologyinfectious diseases (medical specialty)haematopoietic cell transplantationhaematopoiesistransplantation medicine

Impact of Antibiotic Timing on Survival Outcomes in Cd19 and Bcma Car-T Cell Therapy. Blood (2025)

immunotherapyimmune checkpoint inhibitorsantibiotic timingantimicrobial agentsoncologyantibiotic adjuvantmedicinesurvival analysiscancer immunotherapycellular therapycell therapysurvival outcomesimmunologyantibiotics